4171.TWO GeneReach Biotechnology

Healthcare Biotechnology Taiwan OTC Exchange
15.00 TWD
Close of Nov 6, 2026
14.35 23.90
Market cap
TWD 853M
P/E
-
P/B
1.56x
ROE
-3.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 4171.TWO undervalued?

Graham number

The Graham number of GeneReach Biotechnology cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GeneReach Biotechnology fundamental analysis

No fundamental analysis for GeneReach Biotechnology yet.

GeneReach Biotechnology stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GeneReach Biotechnology

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assays, iiPCR Specific Reagents, research reagents and consumables, as well as taco …

Full company profile